A detailed history of Morgan Stanley transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 477,625 shares of MCRB stock, worth $343,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares
477,625
Previous 885,336 46.05%
Holding current value
$343,890
Previous $1.24 Million 70.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.75 - $1.56 $305,783 - $636,029
-407,711 Reduced 46.05%
477,625 $367,000
Q4 2023

Feb 13, 2024

BUY
$0.93 - $2.15 $479,822 - $1.11 Million
515,938 Added 139.67%
885,336 $1.24 Million
Q3 2023

Nov 15, 2023

SELL
$2.33 - $5.07 $213,828 - $465,284
-91,772 Reduced 19.9%
369,398 $879,000
Q2 2023

Aug 14, 2023

BUY
$4.67 - $6.55 $1.25 Million - $1.75 Million
266,954 Added 137.45%
461,170 $2.21 Million
Q1 2023

May 15, 2023

SELL
$4.95 - $6.09 $122,294 - $150,459
-24,706 Reduced 11.29%
194,216 $1.1 Million
Q4 2022

Feb 14, 2023

BUY
$5.09 - $9.05 $506,694 - $900,900
99,547 Added 83.39%
218,922 $1.23 Million
Q3 2022

Nov 14, 2022

SELL
$3.5 - $7.2 $368,413 - $757,879
-105,261 Reduced 46.86%
119,375 $765,000
Q2 2022

Oct 27, 2022

SELL
$2.7 - $7.62 $1 Million - $2.83 Million
-370,885 Reduced 62.28%
224,636 $770,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.62 $1 Million - $2.83 Million
-370,885 Reduced 62.28%
224,636 $770,000
Q1 2022

Oct 27, 2022

BUY
$6.3 - $8.84 $2.34 Million - $3.28 Million
370,885 Added 165.1%
595,521 $4.24 Million
Q1 2022

May 13, 2022

BUY
$6.3 - $8.84 $320,065 - $449,107
50,804 Added 9.33%
595,521 $4.24 Million
Q4 2021

Feb 14, 2022

SELL
$6.02 - $11.43 $823,042 - $1.56 Million
-136,718 Reduced 20.06%
544,717 $4.54 Million
Q3 2021

Nov 15, 2021

BUY
$5.46 - $22.6 $3.72 Million - $15.4 Million
681,435 New
681,435 $4.74 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.